Group 1 - Merck (MRK.US) made a non-binding acquisition offer exceeding $3 billion for MoonLake Immunotherapeutics (MLTX.US), which was rejected, but negotiations may resume [1] - Following the news, MoonLake's stock surged over 30% in after-hours trading, stabilizing at approximately a 20% increase [1] - MoonLake specializes in developing treatments for inflammatory diseases using its proprietary nanobody technology, with its core drug sonelokimab currently in Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis [1] Group 2 - Merck has been reliant on its blockbuster drug Keytruda for growth, but its patent is set to expire in 2028, and revenue from Gardasil in China has been declining [2] - In April, Merck announced plans to invest $1 billion in a new manufacturing facility in the U.S. to ensure Keytruda supply is not affected by tariffs, marking its first internal production site for Keytruda in the U.S. [2] - As of the latest update, Merck's stock experienced a slight decline of 0.07% in after-hours trading [3]
默沙东(MRK.US)超30亿美元收购邀约遭拒 MoonLake(MLTX.US)盘后飙涨20%